Clinical Trials & Research Studies Near You (Updated 6/25)

Study of Alkaptonuria

NCT00005909

Recruiting

The purpose of this study is to gain a better understanding of alkaptonuria and collect medical data on patients who may later participate in new drug trials for this rare genetic disease. In alkaptonuria, a pigment called homogentisic acid collects in bone and connective tissue, causing arthritis and eventually bone fractures, and also causes discoloration in the ears and whites of the eyes. Some patients also develop kidney stones and heart valve problems. Alkaptonuria has not been studied for... Read More

The purpose of this study is to gain a better understanding of alkaptonuria and collect medical data on patients who may later participate in new drug trials for this rare genetic disease. In alkaptonuria, a pigment called homogentisic acid collects in bone and connective tissue, causing arthritis and eventually bone fractures, and also causes discoloration in the ears and whites of the eyes. Some patients also develop kidney stones and heart valve problems. Alkaptonuria has not been studied for decades; and scientists expect to gain comprehensive clinical information using current medical techniques. Patients with alkaptonuria who are at least two years of age may be eligible for this study. Participants will be evaluated at NIH s Clinical Center for 3 to 5 days every 2 to 3 years. They will have a medical history, physical examination, routine blood and urine tests. Blood may also be collected to measure a type of collagen that indicates new bone formation and to analyze DNA for genetic studies. 24-hour urine collections will be done to measure organic acids and homogentisic acid excretion, assess overall kidney function, and evaluate bone metabolism. A total of 89.5 ml (about 6 tablespoons) of blood will be drawn for these studies in adults and 51 ml (about 3 tablespoons) in children. Patients will (may) also have bone X-rays, kidney ultrasound, brain and chest computerized tomography (CT) scans, magnetic resonance imaging (MRI) scans of affected joints, electrocardiograms, echocardiogram, lung function tests, and a hearing test. Photographs of the face and full body (with underwear on) will be taken. As medically indicated, patients will also have consultations with dentistry and ophthalmology, with physical therapy and rehabilitation medicine for arthritis management, and with cardiology for heart valve evaluation. When appropriate, patients may also have dermatology, pulmonology and neurology consultations. The information from this study will enable doctors to better advise patients with alkaptonuria about their disease and treatment options. It will also prepare the way for clinical studies of a new drug that blocks production of homogentisic acid.... Read Less

Gender:

ALL

Ages:

Between 2 years and 115 years

Trial Updated:

06/13/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Alkaptonuria

Register for Updates

Learn More ›

New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

NCT00342589

Recruiting

This study will examine the effectiveness of a new laboratory method for detecting pneumocystis organisms in a salt-water (saline) oral wash. Pneumocystis infection in people with weakened immunity especially patients with HIV infection or cancer, organ transplant recipients and people receiving immune suppressing therapy can cause life-threatening pneumonia. Currently, pneumocystis infection is diagnosed by sputum analysis or bronchoalveolar lavage. For the sputum analysis, patients are induced... Read More

This study will examine the effectiveness of a new laboratory method for detecting pneumocystis organisms in a salt-water (saline) oral wash. Pneumocystis infection in people with weakened immunity especially patients with HIV infection or cancer, organ transplant recipients and people receiving immune suppressing therapy can cause life-threatening pneumonia. Currently, pneumocystis infection is diagnosed by sputum analysis or bronchoalveolar lavage. For the sputum analysis, patients are induced to produce a sputum sample (liquid discharge from the lung) using a saline mist; however, many hospitals lack the expertise to perform this procedure. The second method, bronchoalveolar lavage, involves inserting a flexible tube into the lung and injecting saline to produce a specimen for diagnosis. This method, however, is time-consuming and can be uncomfortable. New techniques may allow the use of an oral wash to diagnose pneumocystis, even though an oral sample contains far fewer organisms than are obtained with the current methods. This study will examine whether new techniques, such as nucleic acid amplification, may enable a simple oral wash to be used effectively for diagnosis of pneumocystis infection. Patients 3 years of age and older with weakened immunity who have acute pneumonia may be eligible for this study. In addition, people at increased risk of infection with pneumocystis, including health care professionals, family members of patients, and other patients in health care facilities, may participate. Participants will have a medical history and review of medical records to determine their health status and determine if they have had recent respiratory problems or documented PCP. They will then provide an oral wash sample. For this procedure, subjects first rinse their mouth well. Then, they vigorously swish 50 milliliters of saline for 5 to 10 seconds and immediately repeat the procedure to provide two specimens. Washes may be requested daily, weekly, monthly, or for a period of time to be specified. Participants will also have two tubes of blood drawn (total of 20 milliliters, or 4 teaspoons) to test for evidence of pneumocystis. Although no other tests are required for this protocol, participants may be asked to provide optional add'l samples, as follows: If a sputum or bronchoalveolar lavage sample is required in the course of the patient s clinical mgmt, enough material will be obtained, if possible, for research purposes as well as what is needed for routine care. An induced sputum sample may be requested just for this protocol. For this procedure, a mask with a saline mist is placed over the face, inducing a cough that, it is hoped, will produce sputum from the lungs.... Read Less

Gender:

ALL

Ages:

Between 3 years and 99 years

Trial Updated:

06/13/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Pneumocystis Infection, Infection, Pneumonia, Pneumocystis, Lung Disease, Fungal, Mycoses

Register for Updates

Learn More ›

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

NCT01036581

Recruiting

Background: - Functional and structural magnetic resonance imaging (MRI) techniques have allowed researchers to map and study how the brain works when at rest and when engaged in specific tasks. MRI scans have provided more information about how drugs affect the brain, and about how drug addiction changes the brain and influences behavior, mood, and thinking processes. To better understand the underlying mechanism of drug addiction and to develop strategies for more effective treatment, researc... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

06/13/2025

Locations: National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland

Conditions: Drug Abuse, Nicotine Dependence

Register for Updates

Learn More ›

Improving White Blood Cell Collection From Healthy Donors

NCT01553214

Recruiting

Background: - White blood cells called granulocytes help the body fight infection. People who have had chemotherapy or bone marrow transplants may have very low numbers of these cells. Transfusions of these cells can help improve the body's ability to fight infection. However, most of the cells are located in the bone marrow or spleen, and are hard to collect from healthy donors. Two drugs, filgrastim and dexamethasone, can help move the cells to the bloodstream to be collected by apheresis. Re... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

06/13/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Allogeneic Granulocyte Donation

Register for Updates

Learn More ›

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT02146170

Recruiting

Background: - Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung and thymic cancers to understand the disease better. This may lead to new ways to diagnose and treat it. Objective: - To collect tissue samples for use in the study of lung cancers. Eligibility: - Adults over age 18 with non-small cell lung cancer, small cell lung cancer, extra pulmonary small cel... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors

Register for Updates

Learn More ›

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288

Recruiting

Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to. Objective: To see if signs of inflammation in CSF help predict a person s response to different drugs. Eligibility: People ages 18 and older who: * Are in protocol 09-I-003... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

06/13/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Multiple Sclerosis

Register for Updates

Learn More ›

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

NCT04302025

Recruiting

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +38 locations

City of Hope Comprehensive Cancer Center, Duarte, California

City of Hope - Orange County Lennar Foundation Cancer Center, Irvine, California

USC Norris Cancer Center, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California

The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California

UC Davis Comprehensive Cancer Center, Sacramento, California

UCSF Helen Diller Family CCC, San Francisco, California

University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center), Aurora, Colorado

Yale Cancer Center, New Haven, Connecticut

MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington, District of Columbia

Moffitt Cancer Center, Tampa, Florida

Northwestern University, Chicago, Illinois

Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois

Northwestern Medicine Cancer Center Delnor, Geneva, Illinois

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois

Boston Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center, Farmington Hills, Michigan

Mayo Clinic, Rochester, Minnesota

Ellis Fischel Cancer Center, Columbia, Missouri

Siteman Cancer Center - Washington University Medical Campus, Saint Louis, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York

Columbia University Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Ohio State University, Columbus, Ohio

AHN Cancer Institute ? Allegheny General Hospital, Pittsburgh, Pennsylvania

Baptist Clinical Research Institute, Memphis, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Kelsey Seybold Clnic, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Baylor College of Medicine, Houston, Texas

Lumi Research, Kingwood, Texas

Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia

Seattle Cancer Care Alliance, Seattle, Washington

Conditions: Non-small Cell Lung Cancer

Register for Updates

Learn More ›

Rare Tumors and Cancer Predisposition in Individuals and Families

NCT05350761

Recruiting

Background: Some people may be prone to develop cancer for many reasons. Factors that affect their risk include the genes they inherit and the environment they live and work in. Researchers want to learn more about the natural history of cancer. Objective: To understand how genes and environmental factors can cause tumors and related conditions. Eligibility: People of any age who: Have tumors of an unusual type, pattern, or number Have a family member with a history of cancer Have been e... Read More

Gender:

ALL

Ages:

All

Trial Updated:

06/13/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations

Conditions: Cancer, Hereditary Neoplasms, Genetic Predisposition to Cancer, Environment

Register for Updates

Learn More ›

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

NCT05785624

Recruiting

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has com... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

06/13/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +113 locations

University of Alabama at Birmingham, Birmingham, Alabama

Banner University Medicine Lung Institute, Phoenix, Arizona

Southern Arizona VA Health Care System NAVREF PPDS, Tucson, Arizona

University of California, San Francisco-Fresno, Fresno, California

University of Southern California Keck School of Medicine, Los Angeles, California

UCLA Rheumatology, Los Angeles, California

University of California, San Francisco Medical Center, San Francisco, California

The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente, Torrance, California

Renstar Medical Research, Ocala, Florida

Central Florida Pulmonary Group, PA, Orlando, Florida

Coastal Pulmonary and Critical Care PLC, Saint Petersburg, Florida

Weston Hospital, Weston, Florida

Piedmont Pulmonary and Sleep Medicine Buckhead, Atlanta, Georgia

GenHarp Clinical Solutions, Evergreen Park, Illinois

Northwestern Medicine - Northwestern Medicine Glen, Glenview, Illinois

IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine, Muncie, Indiana

University of Kansas Medical Center, Kansas City, Kansas

University of Michigan Hospital, Ann Arbor, Michigan

Hannibal Regional Healthcare System HRMG Hannibal, Hannibal, Missouri

Pulmonix LLC, Greensboro, North Carolina

Southeastern Research Center, Winston-Salem, North Carolina

The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Baylor Scott and White Health - Advanced Lung Disease Specialists - Dallas, Dallas, Texas

IntraCare Health Center ? Prestige, Dallas, Texas

El Paso Pulmonary Association Elligo PPDS, El Paso, Texas

McGovern Medical School, Houston, Texas

Baylor College of Medicine, Houston, Texas

University of Utah - PPDS, Salt Lake City, Utah

Centro Médico Dra de Salvo, Buenos Aires, Not set

Consultorios Médicos Dr. Doreski, Ciudad Autonoma Buenos Aires, Not set

Instituto Ave Pulmo, Mar Del Plata, Not set

INSARES, Mendoza, Mendoza City, Not set

Fundacion Scherbovsky, Mendoza, Not set

Instituto Medico Rio Cuarto, Rio Cuarto, Not set

Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Not set

Instituto De Patologias Respiratorias, San Miguel de Tucuman, Not set

Centro de Investigaciones Medicas Tucuman, San Miguel de Tucuman, Not set

Centro de Investigaciones Reumatologicas, San Miguel de Tucuman, Not set

Instituto Del Buen Aire, Santa Fe, Not set

Royal Prince Alfred Hospital, Camperdown, New South Wales

St Vincent's Hospital Sydney, Darlinghurst, New South Wales

Monash Health Monash Medical Centre, Clayton, Victoria

AZORG Campus Aalst-Moorselbaan, Aalst, Not set

CHU de Liège, Liège, Not set

AZ Delta, Roeselare, Not set

L2 Ip - Instituto de Pesquisas Clinicas Ltda - ME, Brasilia, Distrito Federal

Hospital Brasilia, Brasilia, Distrito Federal

Hospital de Clinicas de Porto Alegre HCPA PPDS, Porto Alegre, Pará

Hospital Dia do Pulmao, Blumenau, Santa Catarina

Kelowna Allergy and Respiratory Health Clinic, Kelowna, British Columbia

Dynamic Drug Advancement Ltd., Ajax, Ontario

Dr Anil Dhar Professional Medicine Corporation, Windsor, Ontario

CEC SpA, Nunoa, Not set

Enroll SpA - PPDS, Providencia, Not set

Centro de Investigacion del Maule, Talca, Not set

Hopital Avicenne, Bobigny, Not set

Hopital Louis Pradel, Bron, Not set

Hopital Nord AP-HM, Marseille, Not set

Hôpital Arnaud de Villeneuve, Montpellier, Not set

Hopital Pasteur 2, Nice Cedex 1, Not set

Groupe Hospitalier Bichat Claude Bernard, Paris, Not set

CHU de Reims, Reims, Not set

Evangelische Lungenklinik Berlin, Berlin, Not set

Ruhrlandklinik, Essen, Not set

University General Hospital of Heraklion, Herakleion, Not set

University General Hospital of Larissa, Larissa, Not set

Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Székesfehérvár, Not set

Barzilai Medical Center, Ashkelon, Not set

Shamir Medical Center Assaf Harofeh, Beer Jacob, Not set

Rambam Medical Center, Haifa, Not set

Lady Davis Carmel Medical Center, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Rabin Medical Center, Petah Tikva, Not set

The Chaim Sheba Medical Center, Ramat Gan, Not set

Kaplan Medical Center, Rehovot, Not set

Tel Aviv Sourasky Medical Center PPDS, Tel Aviv-Yafo, Not set

Azienda Ospedaliera Universitaria Senese, Siena, Abruzzo

Presidio Ospedaliero GB Morgagni L Pierantoni, Forli', Emilia-Romagna

Arcispedale Santa Maria Nuova, Reggio Emilia, Emilia-Romagna

Fondazione Policlinico Universitario A Gemelli, Roma, Lazio

Ospedale S. Giuseppe Multimedica, Milano, Lombardia

Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi, Ancona, Marche

Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte

Azienda Ospedaliera Universitaria "Policlinico - Vittorio Emanuele" (Presidio Gaspare Rodolico), Catania, Sicilia

Azienda Ospedaliera Universitaria Careggi, Florence, Toscana

Gachon University Gil Medical Center, Incheon, Not set

The Catholic University of Korea Eunpyeong St. Mary's Hospital, Seoul, Not set

Hanyang University Medical Center, Seoul, Not set

Asan Medical Center - PPDS, Seoul, Not set

Samsung Medical Center - PPDS, Seoul, Not set

CICUM San Miguel, Americana, Jalisco

Bioclinica - Centro Integral En Reumatologia Sociedad Anónima de Capital Variable - PPDS, Guadalajara, Jalisco

Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON

Christchurch Hospital, Christchurch, Not set

Dunedin Hospital, Dunedin, Not set

Waikato Hospital, Hamilton, Not set

SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz, Not set

EMED Centrum Uslug Medycznych Ewa Smialek, Rzeszow, Not set

PULMAG Grzegorz Gasior Marzena Kociolek Spolka Cywilna, Sosnowiec, Not set

Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy, Warszawa, Not set

Dr JM Engelbrecht Trial site, Cape Town, Not set

University of Cape Town Lung Institute UCTLI, Cape Town, Not set

St Augustines Hospital, Durban, Not set

Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona

Hospital Universitario Marques de Valdecilla, Santander, Cantabria

CHUS H Clinico U de Santiago, Santiago de Compostela, LA Coruna

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Clinico San Carlos, Madrid, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Hospital Universitario Virgen de la Victoria, Malaga, Not set

Hospital Universitario Son Espases, Palma de Mallorca, Not set

Far East Memorial Hospital, New Taipei, Not set

Taichung Veterans General Hospital, Taichung, Not set

Taipei Veterans General Hospital, Taipei City, Not set

Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement

Register for Updates

Learn More ›

A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF

NCT06237335

Recruiting

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

06/13/2025

Locations: The University of Alabama at Birmingham, Birmingham, Alabama +22 locations

Conditions: Cystic Fibrosis

Register for Updates

Learn More ›

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908

Recruiting

The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +8 locations

Conditions: Advanced Solid Tumor

Register for Updates

Learn More ›

Cocooned Moms Study

NCT06968650

Recruiting

The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: University Of Miami, Miami, Florida +1 locations

Conditions: Stress, Depression, Pregnancy, Blood Pressure

Register for Updates

Learn More ›

All Clinical Trials

Match to Clinical Trials